Neuroprotection reduces the risk of peri-procedural major strokes and death in octogenarians  by Brennan, Christina et al.
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reveecuiadzetion) without TLR (target lesion reveecuiarization) was higher in those with 
re-trsatment compared to no re-treatment (19.2% vs. 3.4%, p--0.02). 
Conclusions: Re-treatment after gamma radiation Is performed in one-third cases, often 
resulting in additional stent implantation. Re-treatment is associated with increased TVR 
at follow-up, probably due to injury outside the irradiated segment. If re-treatment is 
required, vigorous efforts to avoid injury to inadequately irradiated vessel segments and 
additional stenting should be made. 
No re-treatment Re-treatment p Value 
New stents (%) 12 42 <0.01 
Reference diam (mm) 2.84=0.45 2.86±0.40 0.8 
Lesion length (ram) 18.1 ±8.6 20.1 ±9.1 0.2 
Pre-MLD (mm) 0.60±0.44 0.58±0.42 0.8 
Final MLD (mm) 2.69±0.53 2.68±0.52 0.9 
In-hosp MACE (%) 0 2.1 0.3 
9-month MACE (%) 13.1 11.1 1.0 
g-month death (%) 2.1 0 1.0 
9-month MI (%) 2.1 8.9 0.08 
9-month TVR (%) 12.1 22.2 0.14 
9-month TLR (%) 10.1 6.7 0.8 
9-month TVR without TLR (%) 3.1 17.8 <0.01 
1196-22 Efficacy of Gamma Vascular Brachytherapy for Ostlal 
Versus Nonostlal In Stent Restenotlc Lesions 
Costantino O. Costantini. Alexandra J. Lansky, Roxana Mehran, Martin Fahy, Kazuyuki 
Shirai, Nishi Dave, Gragg W. Stone, George Dangas, Martin B. Leon, Cardiovascular 
Research Foundation, New York Cit~, New York. 
Background: In stent rostenosis (ISR) involving the coronary ostium is associated with 
high recurrence rates after conventional treatment compared to non-ostist lesions. 
Whether Gamma vascular brachytherapy (GVBT) significantly improves these outcomes 
is not known. Methods: Pts with native oetist coronary lesions (N=45) were selected from 
a pooled angiographic database of pts enrolled in Vascular Brechytherapy (VBT)trials for 
treatment of ISR and were compared to 232 pts with non-ostial lesions, matched for 
lesion length. Baseline and follow-up quantitative coronary angiographic (QCA) analysis 
were assessed and compared. Results: At baseline pts with ostial lesions had more com- 
plax lesions (ACC/AHA • BI: 73.3% vs. 53.8%, p<0.05), with more total occlusions 
(8.9% vs. 3.0%, p=0.08) compared to non-ostial pts. QCA results are presented in the 
table. 
Patients with VBT failure had a significant reduction in lesion length regardless the lesion 
location: ostist (14.2±9.49 to 6.94±3.69,p<0.05) and non-ostial (16.66±6.71 to 8.61±6.52, 
p<0.005).There were no difference in stent edge restenosis (6.7% vs. 9.1%,p=0.77) Con- 
clusions: Gamma radiation is at least as effective for treatment of ostial in-stent rest- 
enotic lesions as non-ostial lesions, decreasing rastenosis by 54% compared to non- 
ostial lesions. The difference was not related to edge restenosis. 
QCA analysis Ostial Non-Ostist p Value 
Lesion length Pre(mm) 14.2±9.4 16.6±6.7 0.25 
Lesion length FU(mm) 6.9¢3.6 8.6¢6.5 0.07 
Reference (mm) 2.71 ¢0.39 2.61 ±0.46 0,15 
Final DS% 26.9±14,5 27.8¢12.2 0,67 
FU DS% 36.8±21.7 47.2±25.1 0.009 
Late Loss (mm) 0.31±0.58 0.52±0.70 0.05 
Restenosis (%) 17.8 32.8 0.04 
1196-23 Repeat Intracoronary Radiation for  In-Stent Restenoala 
in Patients Who Failed Radiation Therapy: Re-WRIST 
Ron Waksman, Andrew E. Ajani, Edouard Cheneau, Rosanna C. Chan, Bill G. Bass, 
Katayoun Khosravani, Augusto D. Pichard, Lowell F. Satler, Kenneth M. Kent, Ellen 
Pinnow, Joseph Lindsay, Washington Hospital Center, Washington, Dist. of Columbia. 
Background: Intracoronary Radiation (IR) is proven as an effective therapy to prevent 
recurrences of in-stent restenosis (ISR). However nearly 20% of the patients (pts) 
enrolled in radiation studies for ISR required repeat revasculadzation to the irradiated 
site. Re-WRIST (Washington Radiation for In-Stent Restenosis Trial) is a registry evalu- 
ating the safety and efficacy of re-treatment with IR in pts with refractory ISR. 
Methods: Patients with ISR who had recurrence of stenosis at a previously irradiated 
segment and failed a subsequent additional angioplasty were eligible for re-treatment 
with IR, if evaluated as a poor surgical candidate. In Re-WRIST, the radiation system is a 
0.0030-inch nylon ribbon containing 1921r seeds manufactured by Best Industries deliv- 
ered into a non.centered end lumen delivery catheter (Cordis 4F or Mecitronic 5F). The 
prescribed dose is 15 Gy to a 2 mm radial distance from the center of the source. All pts 
receive 6 months of clopidogrel post-procedure. Patients are followed clinically, anglo- 
graphically and by IVUS at 6 and 24 months. 
Results: At present, 9 pts have been enrolled in the Re-WRIST registry, The mean age 
of the cohort is 65 ± lOyrs (4 males, 3 diabetics and 7 pts had previous CABG). Five ISR 
lesions were in native coronary artedes, 3 in saphenous vein grafts and one in left inter- 
nal mammary artery. The mean time interval between radiation treatments is 18 months 
(range 6.4-28.9) and the mean number of previous interventions to the target lesion is 
4.1 ± 1.5. The radiation was delivered successfully in all pts with no procedural or hospi- 
tal complications. Balloon sngiopleety alone wee performed in 6 of 9 pts, 2 pts were 
treated with the excimer laser and 1 pt with the cutting balloon. None of the pts received 
additional stants. At 30 days, there were no reported clinical events. 
Conclusions: Repeat radiation to the same site using 192-1r for refractory ISR is safe 
and effective at 30 days. Complete 6-month clinical and anglographic follow-up will be 
available at presentation. 
1196-24 Age Is an Important Prsdictor of Clinical Outcomes 
Following Intracoronary Radiation Therapy for In-stent 
Restenoals 
Andrew E. Aiani. Edouard Cheoeau, R. Larry White, Bill G. Bass, Augusto D. Pichard, 
Lowell F. Satier, Kenneth M. Kent, Melanie Odnger, Chades Duncan, Ellen Pinnow, 
Joseph Lindsay, Ron Waksman, Washington Hospital Center, Washington, Dist. of 
Columbia. 
Background: Intracoranary radiation therapy (IRT) reduces the recurrence rate of in- 
stent restenosis (ISR) by inhibition of smooth muscle cell proliferation. The ability of 
these calls to replicate is limited with age due to changes in the tstomeres. The purpose 
of this study was to assess the effect of age on clinical outcomes following IRT for ISR. 
Methods: We evaluated 1275 patients (pts) with 6-month (mo) clinical follow-up who 
were enrolled in radiation tdals for ISR using gamma and beta emitters conducted at the 
Washington Hospital Center. Patients with ISR who were assigned to IRT (N=1025) or 
placebo (N=250) were analyzed In 4 age groups: (<55 yrs, 55-64 yrs, 65-75 yrs, >75 yrs). 
Results: Baseline clinical and angiographic haracteristics were similar within each age 
group of IRT pts, except for a higher rate of diabetes in younger pts (42% in pts <75 yrs 
vs. 30% in pts >75 yrs, p=0.002) and a higher rate of previous CABG in older pts (58% in 
pts >75 yrs vs. 37% in pts <55 yre, p< 0.001). The clinical outcomes at 6 mos for IRT 
treated pts are shown (Table). No effect of age was seen in placebo pts. IRT treated pts 
had reduced MACE compared to placebo in all age groups, driven by reduced target ves- 
sel revasculadzation (TVR). Multivariate analysis detected age as an independent pre- 
dictor of MACE at 6 mths (odds ratio 0.8, CI. 0.70-0.93, p=0.O04). Conclusions: Elderly 
pts (>75 yrs) potentially dedve the maximum benefit from IRT for ISR as recurrent rest- 
enosis is significantly reduced compared to younger pts. 
< 55 yrs 55-64 yrs 65-75 yrs >75 yrs P 
(N=268) (N=.321) (N=314) (N=122) 
Death, % 1 3 4 4 NS 
Q-Wave-MI, % 2 1 1 1 NS 
TLR, % 19 21 13 8 0.002 
TVR, % 28 26 19 16 0.005 
MACE, % 28 28 20 18 0.02 
Late Thrombosis, % 3 2 1 1 NS 
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1197-6 Neuroprotect ion Reduces the Risk of PerI-Procedursl 
Major Strokes and Death in Octogenarians 
Christina Brennan, Gary S. Roubin, Sdram S. lyer, Sara Mgaieth, Paliavi Kumar, Nedim 
AI-Mubarak, Roxana Mehran, George Dangee, Martin B. Leon, Jid J. Vifek, Gishst New, 
Lenox Hill Heart and Vascular Institute, NY, New York, Cardiovascular Research 
Foundation, NY, New York. 
Background: Our previous work in carotid stenting (CS) suggested that patients > 80 
years of age compared with those < 80 are higher- risk for procedural related stroke. 
Since then, we have altered our strategy of performing CS in • 80 years under neuropro- 
tection (NP). The aim of this study was to compare procedural outcomes in patients -> 80 
years with and without distal embolic protection. 
Methods: Thirty- day outcomes (TIA, minor strokes, major strokes and myocardial inf- 
arction) were prospectively examined in those patients > 80 years of age who had under- 
gone CS with and without NP. 
Results: There were no differences in age, % female, presence of risk factors, CAD, 
contraleterel occlusion, and procedural success between the two groups. There were 
more patients in the NP group who were asymptomatic (64% vs. 44%), and with prior 
carotid endartarectomy (23% vs. 10%). 
30 Day Outcomes Without NP With NP 
Patient 91 47 
Minor Stroke 7 (7.7%) 3 (6.4%) 
Major Stroke 6 (6.6%) 0 
Fatal Stroke t (1.1%) 0 
Non- Stroke Death 1 (1.1%) 1 (2.1%) 
Total 15 (16%) 4 (8.5%) 
*P= 0.06 
JACC March 6, 2002 
Conclusion: Carotid stenting in the eldedy population can be done with a markedly low 
incidence of strokes and death. These data also suggest that there is a strong trend with 
NP to reducing minor neurological events. 
11 97-7 P rov is iona l  S tent lng  fo r  Symptomat ic  Intrecranla l  
S tenoe is  Us ing  a Mu lUd lec lp l inary  Team: Acute Resu l ts  
and One-Ysar Outcome 
Stephen R. Ramee. Robert Dawson, Robert Felbe~g, Kevin L. McKinley, Tyrone L. 
Collins, J. S. Jenkins, Mohammed I. Awaed, Christopher J. White, Ochsner Clinic 
Foundation, New Orleans, Louisiana. 
Background: Symptomatic intracranial atherosclerosis has a poor prognosis and current 
medical therapies are often ineffective. Drawing from our experience with coronary inter- 
vention, we theorized that a catheter-based approach could be safe and beneficial in this 
patient population. 
Methods: We retrospectively reviewed the results from all patients undergoing elective 
intrecranial intervention between 4/97-5/01. The muitldisciplinary team included a neuro- 
radiolgist and an interventional cardiologist, and all patients were evaluated pra- and 
pest-procedure by a stroke neurologist. Provisional stenting was performed for complex 
lesion morphology or a suboptimal balloon result. 
Results: Twenty patients (mean age 67, range 45-87 years) were referred for interven- 
tion with intrecranial internal carotid (75%) or vertebrobasilar stenosis (25%). Symptoms 
included TIA (40%), stroke (35%), or both (25%). Ten patients (50%) received balloon 
angioplasfy and 10 (50%) received stents. Coronary equipment was used in all cases. 
The indication for stenting was complex lesion morphology in 7 (70%), and suboptimal 
balloon result in 3 (30%). Procedural and in-hospital success was 100%. There were no 
TIAs or strokes. At 30 days, all patients were alive and 95% had symptomatic improve- 
ment. At last follow-up (mean 12.7, range 2-45 months), symptomatic improvement per- 
sisted in 90% of patients. One late death occurred in a patient with multi-organ failure. 
Fifty percent of our patients had an "unexpected benefit" from the procedure, defined as 
improvement in a chronic neurologic deficit thought to be permanent. 
Conclusion: Intracranial angloplasfy with provisional stenting is both safe and beneficial 
to the majorify of patients in this study with symptomatic intrecranial stenosis. A multldis- 
ciplinary team is the ideal way to manage these patients. Our single center results justify 
a larger controlled prospective tdal to further define who will benefit from this type of 
treatment. 
1197-8 New Focal  I schemle  o f  the  Bra in  A f ter  Carot id  Ar tery  
S tant ing  Despi te  Distal  P ro tec t ion  
Joachim Schofer, Michael Schlueter, Thilo Tuebler, Johann C. Steffens, Giancarlo 
Biamino, Center for Cardiology and Vascular Intervention, Hamburg, Germany. 
To prevent distal embolization during carotid artery stenting (CAS), a variefy of protection 
systems is presently under clinical investigation. Their efficacy needs yet to be estab- 
lished. Methods: In a pilot study, 21 consecutive patients (8 f, 13 m; 68.6 ± 8.5 years) 
underwent diffusion-weighted magnetic resonance imaging (DWMRI) pra and within 24 
hours post elective CAS. Filter-based protection systems were used in 20 patients: Neu- 
roShield (MedNova, n = 10), TRAP (Microvena, n = 4), AngloGuard (Cordis, n = 2), Filter- 
Wire (Boston Scientific, n = 2), and Distal Protection Device (Medtronic AVE, n = 2). In 
the remaining patient, an =endovascular clamping" device (MO.MA, Invatec) was 
employed which enables balloon occlusion of both external and common carotid artery 
prior to treatment of an internal carotid artery lesion. Results: All CAS procedures were 
successfully completed, with the protection devices used as intended. On preinterven- 
tional DWMRI, no patient exhibited signs of recent cerebral ischemia. Postprocedura, 1 
patient experienced transient narrowing of the visual field indicative of retinal ischemia, 
An anatomical correlate was not detected on DWMRI. However, new ischemic foci were 
detected in the cerebral territory supplied by the targeted carotid artery in another 5 
patients (23.8%) who expedencad no clinical sequelae. The protection systems which 
had been in use in these patients were TRAP (n = 2), NeuroShield (n = 1), FiiterWira (n = 
t) and MO.MA (n = 1). Conclusion: Despite protection, clinically silent tocal cerebral 
ischemia is observed in about 25% of CAS procedures. Its etiology remains to be estab- 
lished, and there seems to be no predilection of the type of protection system used. Fur- 
ther investigation is warranted. 
1197-9 Stent  Suppor ted  Carot id  Ar tery  Angloplasty: The Impact  
o f  Renal  Function on the Neuro log ica l  Outcome 
Luis Grubaro, John R. Laird, Jr., Lowell F. Satler, Bryan H. Curry, Lee H. Monsein, Dancia 
Langley, Regina Deible, Ellen E. Pinnow, Joseph Lindsey, Jr., Washington Hospital 
Center, Washington, DisL of Columbia, Rambam Medical Center, Haifa, Israel. 
Background: Stent supported carotid artery angioplasty (SSCA) is increasingly gaining 
acceptance as an aitemative to surgical endarteractomy for the treatment of carotid 
artery stenosis. The impact of chronic renal insufficiency (CRI) on the outcome after this 
procedure is unknown, Methods: A total of 248 consecutive patients underwent 253 pro- 
cedures at our institution. We analyzed the clinical outcome according to calculated craa- 
tinine clearance (CrCI). Normal CrCI (>70 mlJmin) n=93; mild CRI (CRC1=50-69 mL/min) 
n=78; and severe CRI (CrCI<50 mL/min) n=77. Results: Patients with lower CrCI war 
older, more frequently female and had a higher incidence of diabetes. Procedural suc- 
cess was >99% for all three groups. The 30-day neurological complications are shown in 
the Table, Four out of eight patients who had a major stroke had a CrCI <30 mL/min, 
Conclusions: 1) Patients with even mild CRI demonstrated an overwhelmingly high rate 
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of neurological complications. 2) Patients with severe CRI are at a higher risk for major 
neurological complications. 3) New approaches, such as distal protection devices, may 
Age (years) 68 72 76 0.001 
Major stroke 1 (1%) 2 (2.6%) 5 (6.5%) 0.13 
Minor stroke 4 (4.3%) 4 (5.1%) 7 (9.1%) 0.13 
Ipsilateral 4 3 7 0.29 
Contralateral 0 1% 0 0.33 
Permanent 0 0 1% 0.33 
Transient 4 % 3 % 6 % 0.48 
TIA 0 3 (3.9%) 1 (1.3%) 0.13 
Fatal stroke O 0 2 (2.6%) 0.11 
Total neurological events 5 (5.4%) 9 (11.5%) 13 (16.9%) 0.05 
1197-10 Catheter -Based Treatment  Approach  fo r  Pat ients  With 
Acute Stroke  Ine l ig ib le  fo r  In t ravenous  Thrombo lys ie  
Raiesh Subramanian, Stephen R. Ramee, Robert Felberg, Kevin L. McKinley, J. S. 
Jenkins, Tyrone J. Collins, Rachael W. Foley, Robert Dawson, Christopher J. White, 
Ochsner Medical Institutions, New Orleans, Louisiana. 
Background: Despite its effectiveness in acute stroke, intravenous thrombolysis (lysis) 
is used in < 3% of acute strokes. Pts who do not qualify may benefit from a catheter- 
based (CS) approach. 
Methods: We retrospectively reviewed the outcome of all pts with acute stroke ineligible 
for intravenous lysis and referred for CB intervention between 4/96 and 7/01. 
Results: 17 pts (age 35-85 yrs, 65% male) with acute stroke ineligible for intravenous 
lysis were referred for emergent CB intervention by a multidisciplinary stroke team neu- 
rologist. A culprit lesion was identified in 14 of 17 pts (82%). Treatment was initiated at a 
median of 198 rots (40 rots - 5 days) from symptom onset: lysis (5) ; balloon engioplasty/ 
stenting (3); combined lysis and rescue angioplasty (5); systemic anticoagulation (1); no 
culprit lesion - only oral antiplatelet herapy (3). 
NIH stroke scale (NIHSS) and modified Rankin score improved significantly at 30 days 
(table); Wilcoxin score p=0.0005 for NIHSS and p = 0,002 for modified Rankin score. 4 
pts (24%) died within 30 days: 2 (12%) of intrecranial hemorrhage and 2 of non-neuro- 
logic causes. 30 day survival was 76% and excellent outcome with modified Rankin 
score of _< 1 was achieved in 59%. 
Conclusions: Based on this single center experience, CB intervention for acute stroke 
appears safe and feasible with a good clinical outcome among patients ineligible for 
intravenous lysis. Further study for the role of CB therapy in acute ischemic stroke com- 
pared to best medical therapy is warranted. 
Baseline 30 day P value 
NIHSS (0-42) 10.0 ± 5.2 3.3 ± 5,5 0,003 
Modified Rankin Score (0-5) 3.1 ± 1.0 1.4 ± 1.5 0.003 
1197-11 Carot id  Ang iop laaty :  Init ial Exper ience  With the Flow 
Reversa l  Techn ique  fo r  Prevention of Embolic 
Compl ica t ions  
Horst Sieved, Kasja Rape, Wolfgang Pfeil, Christine Rubal, Andreas Fach, Defiev 
Scherar, Hans Spies, Hildegard LiBmann-Jensen, Britta Schuite, Rudi Theis, Kai- 
Friedrich Beykirch, Cardiovascular Center Bethanien, Frankfurt, Germany. 
Background: Complications of carotid aogioplasty usually occur due to embolization of 
arteriosclerotic debris. Reversal of blood flow in the internal carotid artery during anglo- 
plasty and stanting has been suggested to prevent this. 
Patients: Carotid angioplasty and stenting under flow reversal was attempted in 18 
patients (age 66 ± 10). 8 patients had a previous ipsilataral TIA and or stroke. Diameter 
stenosis ranged from 60 to 95 % (77 :t: 10), the length of the lesion ranged from 5 to 25 
mm. At least one lesion contained fresh thrombus. One patient had a contralateral steno- 
sis of > 50% and one patient had a contralataral occlusion. 
Methods: Reversal of blood flow in the internal carotid artery was achieved by occlusion 
of both the common and the external carotid artery during the procedure using the Arte- 
da TM device. During the procedure the blood flowing back into the guiding catheter was 
re-transfused into the femoral vein via a filter. Conventional wires and balloons where 
used. A Wallstent was implanted in all patients. 
Results: The device could easily be introduced into the common carotid artery. Balloon 
occlusion of the common carotid artery as well as the external carotid artery was 
achieved in all patients. The occlusion time ranged between 6 and 37 rain (16 ± 10) and 
was tolerated reasonable in all patients except one, in whom the balloon had to be 
deflated repeatedly during the procedure. Two patients experienced transient neurologi- 
cal symptoms during balloon occlusion without need for interruption of the procedure, In 
all patients angiographic was achieved without immediate complications. In one patient a 
TIA occurred several hours later. Macroscopic debris was found in the filter in 17/18 
patients. 
Conclualona: Flow reversal in the carotid artery for protection of embolism during 
carotid angioplasty is feasible in the majority of patients. Atherosclerotic debris is kept 
back efficiently. If the balloon occlusion is not tolerated, the procedure can be completed 
by deflating the balloon intermittently. As in any other embolic protection device, late 
ischemic events can not be avoided. 
be warranted in this high-risk population. 
Normal CrCl Mild CRI Severe CRI p 
(n=93) (n=Ta) (n=T/) 
